Articles > Legal Deadline Approaching for Zenas BioPharma, Inc. Stockholders
- Class action lawsuits have been filed against Zenas BioPharma, Inc. by multiple law firms.
- Investors who suffered losses on their ZBIO investment should take action before June 16, 2025.
- The lawsuits allege violations of federal securities laws related to Zenas BioPharma's IPO in September 2024.
- Stockholders can seek potential recovery by joining the class action lawsuits.
- Several law firms are actively encouraging Zenas BioPharma investors to secure legal counsel before the deadline.
Several law firms, including Levi & Korsinsky, Rosen, Pomerantz, and Bronstein, Gewirtz, and Grossman, have initiated class action lawsuits against Zenas BioPharma, Inc. (NASDAQ: ZBIO). Investors who have incurred losses on their ZBIO investment are urged to take action before the upcoming deadline of June 16, 2025. The lawsuits allege violations of federal securities laws in connection with Zenas BioPharma's initial public offering (IPO) that took place in September 2024.
Rosen Law Firm, a global investor rights law firm, has reminded purchasers of Zenas BioPharma securities about the crucial lead plaintiff deadline of June 16, 2025, in the securities class action initiated by the firm. Investors who believe they may have suffered financial losses on their ZBIO investment are encouraged to seek legal counsel and potentially join the ongoing litigation for a chance at recovery.
Pomerantz LLP has also announced the filing of a class action lawsuit against Zenas BioPharma, Inc. Investors with losses on their ZBIO investment are advised to contact Danielle Peyton for further information on how to participate in the lawsuit before the deadlines pass. Those who acquired Zenas BioPharma securities during the IPO period are eligible to join the class action and potentially recover damages.
Bronstein, Gewirtz & Grossman, LLC has informed Zenas BioPharma, Inc. shareholders with substantial losses that they have the opportunity to lead a class action lawsuit. The lawsuit aims to recover damages from the defendants for alleged violations of federal securities laws. Investors who purchased or acquired ZBIO securities during the IPO are viable candidates to participate in seeking potential recoveries.
Levi & Korsinsky, LLP is also actively notifying Zenas BioPharma, Inc. investors about the pending class action lawsuit with a lead plaintiff deadline of June 16, 2025. The legal action seeks to recover losses on behalf of investors who were negatively impacted by alleged securities fraud related to Zenas BioPharma's IPO. Stockholders are encouraged to secure legal representation and explore their options in the ongoing litigation against the company.
As the deadline for Zenas BioPharma, Inc. stockholders to join the class action lawsuits approaches, multiple law firms are dedicated to assisting investors in seeking potential recoveries for their losses. It is imperative for affected shareholders to take action before June 16, 2025, to participate in the ongoing legal proceedings and potentially recover damages related to alleged violations of federal securities laws surrounding Zenas BioPharma's IPO.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
Legal Deadline Approaching for Zenas BioPharma, Inc. Stockholders
By KlickAnalytics Data Insights | May 20, 2025 08:01PM ET
Key Points
- Class action lawsuits have been filed against Zenas BioPharma, Inc. by multiple law firms.
- Investors who suffered losses on their ZBIO investment should take action before June 16, 2025.
- The lawsuits allege violations of federal securities laws related to Zenas BioPharma's IPO in September 2024.
- Stockholders can seek potential recovery by joining the class action lawsuits.
- Several law firms are actively encouraging Zenas BioPharma investors to secure legal counsel before the deadline.
Several law firms, including Levi & Korsinsky, Rosen, Pomerantz, and Bronstein, Gewirtz, and Grossman, have initiated class action lawsuits against Zenas BioPharma, Inc. (NASDAQ: ZBIO). Investors who have incurred losses on their ZBIO investment are urged to take action before the upcoming deadline of June 16, 2025. The lawsuits allege violations of federal securities laws in connection with Zenas BioPharma's initial public offering (IPO) that took place in September 2024.
Rosen Law Firm, a global investor rights law firm, has reminded purchasers of Zenas BioPharma securities about the crucial lead plaintiff deadline of June 16, 2025, in the securities class action initiated by the firm. Investors who believe they may have suffered financial losses on their ZBIO investment are encouraged to seek legal counsel and potentially join the ongoing litigation for a chance at recovery.
Pomerantz LLP has also announced the filing of a class action lawsuit against Zenas BioPharma, Inc. Investors with losses on their ZBIO investment are advised to contact Danielle Peyton for further information on how to participate in the lawsuit before the deadlines pass. Those who acquired Zenas BioPharma securities during the IPO period are eligible to join the class action and potentially recover damages.
Bronstein, Gewirtz & Grossman, LLC has informed Zenas BioPharma, Inc. shareholders with substantial losses that they have the opportunity to lead a class action lawsuit. The lawsuit aims to recover damages from the defendants for alleged violations of federal securities laws. Investors who purchased or acquired ZBIO securities during the IPO are viable candidates to participate in seeking potential recoveries.
Levi & Korsinsky, LLP is also actively notifying Zenas BioPharma, Inc. investors about the pending class action lawsuit with a lead plaintiff deadline of June 16, 2025. The legal action seeks to recover losses on behalf of investors who were negatively impacted by alleged securities fraud related to Zenas BioPharma's IPO. Stockholders are encouraged to secure legal representation and explore their options in the ongoing litigation against the company.
As the deadline for Zenas BioPharma, Inc. stockholders to join the class action lawsuits approaches, multiple law firms are dedicated to assisting investors in seeking potential recoveries for their losses. It is imperative for affected shareholders to take action before June 16, 2025, to participate in the ongoing legal proceedings and potentially recover damages related to alleged violations of federal securities laws surrounding Zenas BioPharma's IPO.
For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.